Cellebrite DI Ltd.
At today's price, Cellebrite DI Ltd. (CLBT) is priced for today's economics sustained for ~10.3 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Cellebrite sells digital-intelligence and forensics software to more than 7,000 law enforcement, defense, and intelligence agencies, a subscription business where annual recurring revenue grew 21% to $493 million and subscription revenue rose 23% in the first quarter [Source: Cellebrite Q1 2026 results]. • The business converts that growth to cash unusually well, a trailing free-cash-flow margin around 32%, but the share count is growing roughly 11.5% a year from stock-based compensation, so p
Is CLBT overvalued? See what's priced in →
217 institutional managers reported holding CLBT in 13F filings for the quarter ended 2026-03-31. Together they hold about 50% of the company; the top 10 hold 24%. 48 opened new positions that quarter. Held by FMR (Fidelity), BlackRock, Renaissance Technologies, among others. On the short side, 5.5M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CLBT's share count grew 67.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Last analyzed: June 14, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.